Rothschild Asset Management Inc. trimmed its position in shares of PRA Health Sciences (NASDAQ:PRAH) by 0.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 310,906 shares of the medical research company’s stock after selling 2,134 shares during the period. Rothschild Asset Management Inc. owned about 0.49% of PRA Health Sciences worth $25,793,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Carillon Tower Advisers Inc. bought a new position in PRA Health Sciences in the fourth quarter worth about $80,506,000. Bank of New York Mellon Corp raised its stake in PRA Health Sciences by 185.6% in the fourth quarter. Bank of New York Mellon Corp now owns 911,828 shares of the medical research company’s stock worth $83,041,000 after buying an additional 592,595 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in PRA Health Sciences by 70.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 737,430 shares of the medical research company’s stock worth $67,158,000 after buying an additional 304,486 shares in the last quarter. Eagle Asset Management Inc. raised its stake in PRA Health Sciences by 12.4% in the fourth quarter. Eagle Asset Management Inc. now owns 1,242,648 shares of the medical research company’s stock worth $113,059,000 after buying an additional 137,528 shares in the last quarter. Finally, Icon Advisers Inc. Co. raised its stake in PRA Health Sciences by 279.1% in the fourth quarter. Icon Advisers Inc. Co. now owns 153,542 shares of the medical research company’s stock worth $13,983,000 after buying an additional 113,042 shares in the last quarter. 98.76% of the stock is owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on PRAH. Credit Suisse Group reissued an “outperform” rating and issued a $104.00 price target (up from $101.00) on shares of PRA Health Sciences in a research note on Thursday, February 22nd. KeyCorp reissued a “buy” rating and issued a $100.00 price target on shares of PRA Health Sciences in a research note on Wednesday, January 31st. BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 27th. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Finally, Mizuho downgraded shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target for the company. in a research note on Wednesday, January 24th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $95.67.
Shares of NASDAQ PRAH opened at $79.95 on Friday. PRA Health Sciences has a fifty-two week low of $79.98 and a fifty-two week high of $80.80. The company has a market cap of $5.14 billion, a price-to-earnings ratio of 24.59, a price-to-earnings-growth ratio of 1.24 and a beta of 0.50. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 1.29.
PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, April 25th. The medical research company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.84 by $0.01. PRA Health Sciences had a net margin of 4.07% and a return on equity of 23.06%. The business had revenue of $701.80 million during the quarter, compared to the consensus estimate of $694.73 million. During the same quarter last year, the firm earned $0.62 earnings per share. The business’s revenue for the quarter was up 43.9% on a year-over-year basis. sell-side analysts anticipate that PRA Health Sciences will post 3.81 EPS for the current year.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.